Introduction
Canada has recently strengthened its Scientific Research & Experimental Development (SR&ED) regime: CCPCs (Canadian-controlled private corporations) can now claim an enhanced 35% investment tax credit on a higher threshold of expenditures and public corporations may also qualify. (canada.ca)
For investors, startup founders and biotech firms, structuring your entity carefully can unlock substantial tax savings and maximize liquidity.
Key enhancements – what’s new?
- Annual expenditure limit for CCPCs increased from $3M to $4.5M for enhanced SR&ED ITC. (canada.ca)
- Taxable capital thresholds raised: prior-year caps increased to $15M and $75M. The phase-outs apply beyond those thresholds. (canada.ca)
- Inclusion of public corporations: public companies can now access SR&ED enhanced refundable credits. (canada.ca)
- Capital costs pre-2014 eligibility reinstated for property acquired after December 15, 2024. This affects older fixed assets eligible for CCA and SR&ED income deduction. (canada.ca)
Entity setup matters – structuring for optimal benefit
| Scenario | CCPC vs non-CCPC | Public vs Private | Age/Type of property/assets |
|---|---|---|---|
| A startup rooted in Canada with private shareholders | Best as a CCPC to get full enhanced credit (35%) | N/A | New property acquired after Dec 15, 2024 benefits from reinstated eligibility |
| Expanding or listed company | If you lose CCPC status (public or taxable capital too high), credit begins phasing out | Public corporations now have refundable portion – still beneficial | Ensure assets meet new eligibility rules under pre-2014 regime reinstatement |
Practical actions & planner checklist
- Ensure corporate structure meets CCPC requirements: be Canadian-controlled, private, shareholders domestic, etc. Otherwise, credits may reduce or disappear.
- Track taxable capital carefully**: large assets or growth in capital may push you over the thresholds prematurely.
- Time asset acquisitions: property acquired after Dec 15, 2024 gains extra eligibility. If possible, accelerate purchases to qualify.
- Maintain R&D records meticulously: lab notes, experimental designs, expenses. For public corporations, refundability is especially important—ensure documentation supports refund claims.
- Consider public-vs-private status trade-offs: if raising capital via IPO, weigh loss of CCPC status vs refundable credits access.
Example case study
Biotech Startup “BioNova Inc.” BioNova is a private, CCPC located in Ontario. It plans $5M of SR&ED eligible expenditures this fiscal year. Under the new rules, up to $4.5M of that qualifies for a 35% credit, yielding ~$1.575M in credit on that portion. The extra $0.5M still receives credit, but possibly at lower rate or reduced phase-out. They avoid losing CCPC status by keeping taxable capital within threshold. If instead they go public, they still qualify, but will use refundable portion and likely different phase-outs.
Risks and compliance traps
- Overestimating eligible expenditures: ensure activities meet SR&ED criteria.
- Losing CCPC status due to public shareholders or capital: can reduce benefit rates.
- Missing deadlines: claims must follow CRA rules, asset availability dates matter.
- Underreporting capital cost basis or misunderstanding eligibility of older assets.
Conclusion
If you're considering entity formation or restructuring in Canada, recent changes in SR&ED regime demand attention. With strategic structuring—focusing on CCPC status, timing of asset acquisitions, and proper capital management—you can significantly increase your tax benefit while staying compliant.